In 2012, the Alzheimer’s disease (AD) market was dealt a huge blow following negative results from pivotal Phase III trials of Pfizer and J&J’s bapineuzumab and the intravenous formulation of the drug was discontinued. Expectations for beta-amyloid theory were low following this failure; however results from Eli Lilly’s solanezumab have offered a glimmer of hope for the AD community. Although missing its primary endpoints, pooled analysis of solanezumab data in mild patients showed a statistical significant slowdown of cognitive decline.
With novel therapies slowly emerging from the pipeline, such as beta secretase and tau therapies, and positive research into biomarkers to aid early AD diagnosis there is renewed hope as the market enters a new phase of development.
The KOL Insight module of Alzheimer’s Disease: Beta-amyloid light fases to leave development hole is compiled from exclusive, in-depth interviews with the world’s leading KOLs in AD. It identifies and analyses the major factors, advances and trends currently influencing the AD treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future AD management.
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how AD clinical research will shape the future market.
Alzheimer’s disease: Beta-amyloid light fades to leave development hole examines the most prominent insights gained from the field’s key opinion leaders. The results of FirstWord’s research and analysis will help you to:
Alzheimer’s disease: Beta-amyloid light fades to leave development hole answers key questions including:
•What do KOLs make of the sola and bapi failures?
Alzheimer’s Disease Panel of Key Opinion Leaders
FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. The AD panel assembled for this Therapy Trends research is drawn from North America and Europe professionals:
Stay a step ahead with Therapy Trends Event Assessments. Over the next 12 months, you will receive updated qualitative analysis each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
This report provides a qualitative overview of the current and future Alzheimer’s disease (AD) market. Information was gathered from telephone discussions held with twelve key opinion leaders (KOLs), from across the major AD markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also dictate the dynamics of Pharma markets in other countries.
In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.
Subject matter for discussion in the interviews covered future diagnostic and therapeutic strategies for AD, the future of AD drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing AD drug classes, the cost of newer drugs and other concerns in the therapy area.
Table of Contents
for Therapy Trends: Alzheimer's Disease - Breaking new ground in disease modification [Published by FirstWord Pharma]
1.Current Alzheimer’s disease marketplace
2.Current treatment landscape
3.Reimbursement of key Alzheimer’s disease brands
5.Aricept (donepezil; Eiasi/Pfizer) trends
6.Exelon (rivastigmine; Novartis) trends
7.Razadyne (galantamine; Johnson & Johnson/Shire) trends
8.Namenda/Ebixa (memantine; Forest/Merz/Lundbeck) trends
9.Current treatment algorithm
10.Unmet needs in Alzheimer’s disease
11.Pipeline Alzheimer’s disease therapies
13.Solanezumab (LY2062430, Eli Lilly) trends
14.Gammagard (immune globulin IV [human], Baxter) trends
15.Gantenerumab (Roche) trends
16.Bapineuzumab (Johnson & Johnson/Pfizer) trends
17.BACE inhibitor overview
18.MK-8931 (Merck) trends
19.Future prescribing trends
20.Future developments in Alzheimer’s disease
21.Clear definition of disease-modifying is required
22.Improved understanding of underlying disease etiology
23.Therapies targeting tau
24.Gene therapy as a treatment option
25.Enrolment of trials will be more important for success
26.Identification of patients earlier in disease course for intervention
27.Development of biomarkers will aid diagnosis and treatment
Number of Pages
|Title||Date Published||Price from||More Details|
|Global Gene Therapy Partnering Terms and Agreements 2010 to 2016|
The Global Gene Therapy Partnering Agreements 2010-2016 report provides an understanding and access ...
|01 Oct 2016 by Current Partnering||USD $2,995||More Info|
|Pathfinder Cell Therapy, Inc. (PFND) - Financial and Strategic SWOT Analysis Review|
SummaryPathfinder Cell Therapy, Inc. (Pathfinder) is a regenerative medicine company that develops n...
|08 Nov 2015 by Global Data||USD $300||More Info|
|Wright Therapy Products - Medical Equipment - Deals and Alliances Profile|
SummaryWright Therapy Products (Wright) is a medical device manufacturing company that provides pneu...
|03 Nov 2015 by Global Data||USD $250||More Info|
|Physician Views: What scope for the next oral RA therapy?|
Scope The rheumatoid arthritis (RA) market is one of the largest in the pharmaceutical sector and is...
|01 Apr 2015 by FirstWord Pharma||USD $695||More Info|
|Physician Views: How comfortable are doctors with the commercial use of gene therapy?|
Scope Gene therapy has been around for decades, yet in a sense the concept has recently been made to...
|23 Mar 2015 by FirstWord Pharma||USD $695||More Info|
|Physician Views – Defining a suitable NASH therapy|
Scope Excitement around the opportunity for therapies that are designed to treat nonalcoholic steato...
|04 Mar 2015 by FirstWord Pharma||USD $695||More Info|
|Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?|
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
|25 Nov 2014 by FirstWord Pharma||USD $695||More Info|
|Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?|
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
|13 Jul 2014 by FirstWord Pharma||USD $695||More Info|
|Physician Views: Are neurologists ready to embrace gene therapy?|
Scope As recently noted by Forbes, the biotech bull market of 2013 has helped to revive an approach ...
|11 Jun 2014 by FirstWord Pharma||USD $695||More Info|
|Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?|
ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
|01 Oct 2013 by FirstWord Pharma||USD $695||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.